Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
Get Alerts MDGL Hot Sheet
Join SI Premium – FREE
CONSHOHOCKEN, Pa., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in three upcoming investor conferences:
SVB Securities Global Biopharma Conference4:20 pm ET on Tuesday, February 14, 2023.
Cowen Annual Healthcare Conference2:50 pm ET on Monday, March 6, 2023.
Oppenheimer Annual Healthcare Conference 10:40 am ET on Monday, March 13, 2023.
The presentations will be webcast and archived recordings will be available for replay in the Investors section of the Madrigal website after the events.
About Madrigal PharmaceuticalsMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist designed to target key underlying causes of NASH in the liver. For more information, visit www.madrigalpharma.com.
Investor Contact Alex Howarth, Madrigal Pharmaceuticals, Inc., [email protected]
Media ContactChristopher Frates, Madrigal Pharmaceuticals, Inc., [email protected]
Source: Madrigal Pharmaceuticals, Inc.Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Starts Madrigal Pharmaceuticals (MDGL) at Underperform, 'pivoting to Rezdiffra commercial dynamics'
- Company announcement no 8 Idavang 2024 Annual General Meeting 26-04-2024
- RESULT OF RIKSBANK AUCTIONS GOVERNMENT BONDS
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!